HOUSTON, May 11, 2021 /PRNewswire/ -- CNS
Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"),
a biopharmaceutical company specializing in the development of
novel treatments for primary and metastatic cancers of the brain
and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS
Pharmaceuticals, will present at the Q2 Virtual Investor Summit on
Tuesday, May 18th at
12:30 PM ET.
In addition to the presentation, management will be available to
participate in virtual one-on-one meetings with qualified members
of the investor community who are registered to attend the
conference. For more information about the conference, please visit
the conference website.
A live video webcast will be accessible on the Events page in
the Investors section of the Company's website (www.cnspharma.com)
and will be archived for 90 days following the event.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is developing novel treatments for primary
and metastatic cancers of the brain and central nervous system. Its
lead drug candidate, Berubicin, is proposed for the treatment of
glioblastoma multiforme (GBM), an aggressive and incurable form of
brain cancer. CNS holds a worldwide exclusive license to the
Berubicin chemical compound and has acquired all data and know-how
from Reata Pharmaceuticals, Inc. related to a completed Phase 1
clinical trial with Berubicin in malignant brain tumors, which
Reata conducted in 2006. In this trial the overall response rate of
stable disease or better was 44%. This 44% disease control rate was
based on 11 patients (out of 25 evaluable patients) with stable
disease, plus responders. One patient experienced a durable
complete response and remains cancer-free as of Feb. 20, 2020. These Phase 1 results represent a
limited patient sample size and, while promising, are not a
guarantee that similar results will be achieved in subsequent
trials. During 2021, CNS expects to commence a Phase 2 clinical
trial of Berubicin for the treatment of GBM in the U.S., while a
sub-licensee partner undertakes a Phase 2 trial (with extensive PK)
in adults and a first-ever Phase 1 trial in pediatric GBM patients
in Poland. Its second drug
candidate, WP1244, is a novel DNA binding agent that has shown in
preclinical studies that it is 500 times more potent than the
chemotherapeutic agent daunorubicin in inhibiting tumor cell
proliferation.
For more information, please visit www.CNSPharma.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/cns-pharmaceuticals-to-present-at-the-q2-virtual-investor-summit-301288082.html
SOURCE CNS Pharmaceuticals, Inc.